Evidence-Based Complementary and Alternative Medicine

Evidence-Based Complementary and Alternative Medicine / 2019 / Article

Research Article | Open Access

Volume 2019 |Article ID 9151070 | 7 pages | https://doi.org/10.1155/2019/9151070

Adenine Inhibits the Growth of Colon Cancer Cells via AMP-Activated Protein Kinase Mediated Autophagy

Academic Editor: Ronald Sherman
Received06 Jul 2019
Accepted13 Aug 2019
Published12 Sep 2019


Background. Adenine is involved in a variety of cell biological processes and has been explored for pharmacological uses. Its therapeutic use for managing cancer is of great interest. In the present study, we investigated the anticancer effects of adenine and the underlying mechanism in colon cancer cells. Methods. Cell viability was measured using the MTT assay. Levels of phosphorylation and protein expression were determined using western blotting. qPCR was carried out to determine the changes in mRNA expression of genes of interest. Results. Adenine significantly inhibited the viability of colon cancer cells, HT29 and Caco-2 cells, in a dose-dependent manner. Adenine induced significant apoptosis in HT29 cells, whereas Caco-2 cells exhibited less apoptotic responses. The data showed that adenine activated AMP-activated protein kinase (AMPK) signaling contributing to autophagic cell death through mTOR in both colon cancer cell lines. Conclusions. Our findings suggest that adenine inhibits the growth of colon cancer cells. Anticancer activity of adenine in colon cancer cells is attributable to the activation of apoptotic signaling and in turn the AMPK/mTOR pathway. Adenine represents a natural compound with anticancer potency.

1. Introduction

Colorectal cancer (CRC) is one of the leading malignancies, which is expected to account for 2.2 million new cases and 1.1 million deaths worldwide in 2030 [1]. Approximately, 40% of patients with CRC present localized-stage disease at diagnosis, which is curable with surgical modality. 20% of CRC patients have metastasis at diagnosis. For patients with advanced CRC, treatment options include chemotherapy, radiation therapy, and biological therapy in combination with surgical modalities. Although these therapeutic regimens achieve somewhat satisfactory local disease control, effective regimens for metastatic CRC patients with liver metastases from colorectal cancer are limited.

Adenine is a purine derivative which is synthesized in the liver in humans. It also exists in foods such as brewer’s yeast and vegetables. Adenine forms several biological compounds involved in a variety of cellular physiological processes such as adenosine triphosphate (ATP) in cellular respiration and deoxyribonucleic acid (DNA) in protein synthesis. Adenine also forms as a component of nicotinamide adenine dinucleotide (NAD) and flavin adenine dinucleotide (FAD), which are involved in metabolism. In addition to its physiological functions, adenine has also been demonstrated for its pharmacological properties. Recent studies have shown that adenine attenuates allergic responses [2, 3]. Adenine has been reported to exert anti-inflammatory activity in different experimental settings [4, 5]. Adenine improves the survival of rat Purkinje cells and enhances the storage of erythrocyte in whole blood [68]. Recently, adenine has been explored for its anticancer property in several types of cancer cell lines. Adenine has been suggested to induce cell cycle arrest in cancer cells, leading to cell death [9, 10]. However, the mechanism by which adenine inhibits the proliferation of cancer cells is sketchy. It is of interest to explore the inhibitory effect of adenine on the growth of colorectal cancer cells and to determine the underlying mechanism.

In this study, we investigated the effects of adenine against the proliferation of colon cancer cells. We explored the possible mechanisms underlying the anticancer activity of adenine in colorectal cancer cells. Inhibition of cell viability was assessed with focus on apoptosis transcriptionally and translationally. Involvement of AMP-activated protein kinase (AMPK) in anticancer property of adenine was also investigated.

2. Materials and Methods

2.1. Cell Culture

Human colon adenocarcinoma cell lines, HT29 (ATCC HTB-38) and Caco-2 (ATCC HTB37), were maintained and cultured in Dulbecco’s Modified Eagle’s Medium (DMEM, Gibco-BRL) supplemented with 10% fetal calf serum (FCS; Gibco-BRL) and 100 μg/mL penicillin/streptomycin at 37°C. For treatment with adenine (Sigma-Aldrich, St. Louis, MO, USA), cells were initially seeded in 6-well culture plates at a density of 1 × 105 cells/mL in a total volume of 2 mL and cultured overnight to reach approximately 80% confluence. Adenine treatments were carried out by incubating cells with adenine at designated concentrations (0, 0.1, 1, 5, and 10 mM) for 24 h or 48 h. The resulting cells were washed with phosphate-buffered saline (PBS) and collected for subsequent experiments.

2.2. Cytotoxicity Assay

The MTT assay was conducted to evaluate the cytotoxicity of adenine. In brief, cells were treated with adenine for 24 hours, and culture medium was subsequently aspirated, followed by incubation with MTT (0.5 mg/mL) at 37°C for 4 h. Removing the supernatant, formazan in culture was dissolved in isopropanol and analyzed spectrophotometrically at a wavelength of 563 nm. The number of viable cells was directly proportional to the concentration of formazan and was calculated in comparison with untreated cells.

2.3. Western Blotting

Cells were lysed using a lysis buffer containing 50 mM Tris-HCl, pH 7.5, 1% Nonidet P-40, 1 mM phenylmethylsulfonyl fluoride, and 1 mM NaF supplemented with protease inhibitor cocktail (Roche, Germany). The resulting cell lysate was centrifuged at 20,000 g for 15 min. Resulting supernatants were collected and assessed for protein concentration using the BCA method. 20 μg of the crude protein was subjected to a 12.5% SDS-polyacrylamide gel and subsequently transferred onto a nitrocellulose membrane (Millipore, MA, USA). The resulting membranes were blocked with 5% (w/v) skimmed milk in PBS followed by incubation with primary antibodies (Cell Signaling Technology, MA, USA) at a ratio of 1 : 1000, which were against human cleaved caspase-3, cleaved caspase-8, poly (ADP-ribose) polymerase (PARP), phosphate-AMPK, AMPK, mammalian target of rapamycin (mTOR), phosphate-mTOR (p-mTOR), and glyceraldehyde 3-phosphate dehydrogenase (GAPDH), respectively. Blots were incubated with peroxidase-conjugated secondary antibodies, and antigen-antibody complexes were displayed using ECL chemiluminescence (Millipore, MA, USA).

2.4. Quantitative Real-Time PCR

Total RNA was extracted using TRIzol reagent (Ambion, CA) in accordance with the manufacture’s instruction. RNA levels were measured using the Qubit® RNA Assay Kit (Invitrogen, CA). Reverse transcription was conducted in a 20 μL reaction containing 200 ng of total RNA using cDNA reverse transcription kits (Applied Biosystems, CA), and quantification of genes of interest were evaluated using the ABI 7900HT system (Applied Biosystems) (Table 1).

GeneForward primer (5’–3’)Reverse primer (3’–5’)


2.5. Statistical Analysis

Student’s t-test was performed to calculate the statistical significance between treatment groups and controls. Data were presented as mean ± SD of the three independent experiments using SigmaPlot 10 (Systat Software, San Jose, CA). values less than 0.05 were considered statistically significant.

3. Results

3.1. Adenine-Inhibited Growth of Colorectal Cancer Cells

Effects of adenine on the growth of colorectal cancer cells were determined in HT29 and Caco-2 cells using the MTT assay. HT29 and Caco-2 cells were treated with adenine at different concentrations and analyzed for viability. We found that adenine inhibited the growth of two colorectal cell lines in a dose-dependent manner, showing a significant decrease in viability to 58.4 ± 3.8% and 59.4 ± 2.6%, of the controls in presence of 10 mM of adenine for 24 hours, respectively (Figure 1). The prolonged treatment for 48 hours with adenine resulted in a greater inhibition of cell viability, which was 48.1 ± 2.5% and 56.1 ± 2.7% of the controls in presence of 10 mM of adenine, respectively. The 50% inhibitory concentration (IC50) was calculated for HT29 and Caco-2 cells, resulting as 2.838 mM and 22.198 mM, respectively.

3.2. Adenine-Induced Apoptosis in Colon Cancer Cells

We next investigated the possible underlying mechanism of growth inhibition in both colorectal cancer cell lines in response to adenine treatment. We evaluated the induction of apoptosis based on the changes in levels of apoptotic biomarkers. As shown in Figure 2(a), a significantly increased level of cleaved caspase-3 was found in HT29 cells treated with 5 and 10 mM of adenine compared with that of controls. The results also showed that adenine treatment led to increased cleaved caspase-8 levels and significant cleavages of PARP in HT29 cells dose-dependently. Unexpectedly, Caco-2 cells were found to have relatively less induction of apoptosis in response to adenine treatment (Figure 2(b)). Given the activation of caspase cascades, we next investigated whether adenine treatment alters the expressions of apoptosis-related genes such as antiapoptotic protein Bcl-2 and the proapoptotic proteins. As shown in Figure 2(c), the ratio of Bax to Bcl-2 mRNA was remarkably increased in the cells treated with adenine at high concentrations in comparison with that of controls. Interestingly, HT29 cells were relatively more affected by adenine at high concentrations in comparison to Caco-2 cells (Figure 2(c)).

3.3. Adenine-Activated AMPK and -Regulated Autophagic Signaling in Colon Cancer Cells

Adenine has been reported to upregulate AMPK signaling and in turn activate the biological activity [11, 12]. We hypothesized that adenine inhibits the growth of colon cancer cells through activating AMPK signaling. HT29 and Caco-2 cells were treated with adenine at serial concentrations, and degree of phosphorylation of AMPK and mTOR was analyzed. We found that treatment with adenine resulted in increased levels of AMPK phosphorylation in HT29 and Caco-2 cells in a dose-dependent manner (Figure 3). We also found that the increase in AMPK phosphorylation was associated with a decrease in the level of phosphate-mTOR.

It is known that autophagy is inhibited by mTOR. The role of autophagy in adenine-induced cell death in colon cancer cells was investigated. The results showed that exposure to adenine at concentrations of 5 mM and 10 mM led to an elevated ratio of Atg5 to Bcl-2 mRNA compared with that of controls in HT29 and Caco-2 cells, respectively (Figure 4(a)). The ratio of autophagy-related genes, Beclin1 and Bcl-2, in adenine-treated colon cancer cells was increased in a dose-dependent fashion (Figure 4(b)). The influence of adenine treatment on autophagosome was also determined as in the level of LC3-II using western blotting. Levels of LC3-II were significantly increased in association with increasing concentrations of adenine in HT29 and Caco-2 cells (Figure 4(c)).

3.4. Adenine Inhibited the Growth of Colon Cancer Cells via AMPK-Mediated Autophagy

We found that AMPK activation was associated with induction of autophagy in presence of adenine; thus, effects of adenine-induced AMPK activation on the growth of colon cancer were investigated. The results showed that increased phosphorylation of AMPK in both colon cancer cell lines treated with adenine were restored in the presence of AMPK inhibitor, dorsomorphin, at a concentration of 5 μM corresponding with increased mTOR phosphorylation (Figure 5(a)). Cotreatment with dorsomorphin significantly restored the viability of colon cancer cells treated with 10 mM adenine (Figure 5(b)).

4. Discussion

In the present study, we demonstrate that adenine inhibits the growth of human colon cancer cells via induction of apoptosis and autophagy. We found that adenine induced different degrees of apoptosis depending on the genotype of colon cancer cells. The inhibition of cell growth in colon cancer cells is associated with AMPK activation. Our results reveal that the inhibitory effect of adenine on proliferation of colon cancer cell is attributed to the activation of AMPK signaling.

Adenine, known as vitamin B4, has attracted much attention as a therapeutic agent based on its biochemical property. Its use has been explored as treatment for malignancies. Adenine has been demonstrated to induce apoptosis and cell cycle S-phase arrest in hepatocellular carcinoma cells and cervical cancer cells [9]. Chen et al. reported that adenine induced G2/M cell cycle arrest and autophagy in erythroleukemia K562 cells [10]. It is suggested that adenine-induced inhibition of cancer cell growth varies greatly depending on the type of cancer cells. Apoptosis plays a critical role in cancer development. Abnormal apoptosis is considered to contribute to the pathogenesis of colorectal cancer and resistance to treatments in particular. In this study, we found that HT29 cells are relatively more sensitive to adenine treatment than Caco-2 cells as a result of different degree of apoptotic responses. Our findings showed that adenine treatment led to increased mRNA ratio of Bax to Bcl2 and elevated levels of cleaved caspase-3 and caspase-8, suggesting that adenine could affect the expression of Bcl2 proteins and activate apoptotic pathway in HT29 cells. Our data indicate that adenine induced significant apoptosis in colorectal adenocarcinoma HT29 cells, a p53 mutant, whereas Caco-2 cells, a p53-null cell line, exhibited less apoptosis. This finding is in agreement with the previous study showing adenine fails to induce apoptosis in leukemia K562 cells which are p53-negative [10]. It is suggested that p53 status may play a role in responsiveness to adenine treatment in the aspect of apoptosis. In addition, treatment with adenine for 48 hours was shown to have a relatively high inhibitory rate in HT29 compared with Caco-2 cells, suggesting that the other cell death processes may contribute to the adenine-induced inhibition in colon cancer cells such as autophagy. Further studies are necessary to elucidate the involvement of p53 in adenine-associated inhibition of colon cancer cells.

AMP-activated protein kinase is known for its role in regulation of the protein and lipid metabolism as a conserved energy sensor [13]. Recently, AMPK signaling has been considered as a target process for cancer prevention and therapy [14]. One of the growth signaling pathways regulated by AMPK is the mammalian target of rapamycin (mTOR) pathway, which controls a variety of biological processes involved in cell survival, migration, and metabolism. Activation of AMPK has been shown to suppress the mTOR signaling leading to, in part, the activation of autophagy. Several studies have reported that activation of AMPK induces autophagic cell death in various cancer cells via suppression of mTOR [1519]. Exogenous adenine increases the expression and translocation of glucose transporter 4, enhances the cellular glucose uptake, and elevates the intracellular ATP level [11]. Adenine has been demonstrated to induce AMPK activation in different types of cells [12, 2022]. A recent study has shown that adenine inhibited the growth of leukemia K562 cells via AMPK activation. In our study, we demonstrated that adenine significantly induced AMPK activation and inhibited the phosphorylation of downstream mTOR in both colon cancer cell lines. In addition, we showed an increased level of LC3-II with corresponding elevated expressions of Atg5 and Beclin in HT29 and Caco-2 cells after exposure to adenine. The findings suggest that adenine triggers autophagic cell death in colon cancer cells in present setting. Adenine-inhibited cell proliferation in both colon cancer cell lines was restored with increased levels of mTOR phosphorylation in the presence of AMPK inhibitor dorsomorphin. These findings are in consistent with the previous study showing adenine-induced autophagy via AMPK signaling corresponding with changes in the mTOR level in leukemia [10]. Autophagy has been shown to have dual and contradictory roles in carcinogenesis. In addition to cell death, autophagy is shown to provide a backup energy source for the survival and expansion of tumor cells, particularly cancers at advanced stages [2326]. In the present experimental setting, it is indicated that adenine activates AMPK subsequently contributing to autophagic cell death in colon cancer cells. Nevertheless, treatment with dorsomorphin incompletely reversed the inhibited cell growth, suggesting that adenine may suppress colon cancer cells via AMPK-independent pathways.

In conclusion, we show evidence that adenine significantly inhibits the proliferation of colorectal cancer cells through synergistically in part apoptosis and autophagy. The adenine-induced autophagic cell death is AMPK-dependent in colon cancer cells, whereas apoptosis is attributed to p53 status. By manipulating both arms of apoptotic and autophagic signaling, adenine represents a promisingly effective therapeutic agent against human colorectal cancers. Further studies are required to elucidate the role of p53 in adenine-induced apoptosis in colon cancer cells.

Data Availability

The data used to support the findings of this study are included within the article.

Conflicts of Interest

The authors declare that there are no conflicts of interest.


  1. M. Arnold, M. S. Sierra, M. Laversanne, I. Soerjomataram, A. Jemal, and F. Bray, “Global patterns and trends in colorectal cancer incidence and mortality,” Gut, vol. 66, no. 4, pp. 683–691, 2017. View at: Publisher Site | Google Scholar
  2. T. Hosoi, S. Ino, F. Ohnishi et al., “Mechanisms of the action of adenine on anti-allergic effects in mast cells,” Immunity, Inflammation and Disease, vol. 6, no. 1, pp. 97–105, 2018. View at: Publisher Site | Google Scholar
  3. P. Silwal, K. Shin, S. Choi et al., “Adenine suppresses IgE-mediated mast cell activation,” Molecular Immunology, vol. 65, no. 2, pp. 242–249, 2015. View at: Publisher Site | Google Scholar
  4. M. G. Scioli, A. Bielli, S. Agostinelli et al., “Antioxidant treatment prevents serum deprivation- and TNF-α-induced endothelial dysfunction through the inhibition of NADPH oxidase 4 and the restoration of β-oxidation,” Journal of Vascular Research, vol. 51, no. 5, pp. 327–337, 2014. View at: Publisher Site | Google Scholar
  5. P. Silwal, K. Lim, J.-Y. Heo, J. I. Park, U. Namgung, and S.-K. Park, “Adenine attenuates lipopolysaccharide-induced inflammatory reactions,” The Korean Journal of Physiology & Pharmacology, vol. 22, no. 4, pp. 379–389, 2018. View at: Publisher Site | Google Scholar
  6. S. Watanabe, Y. Yoshimi, and M. Ikekita, “Neuroprotective effect of adenine on purkinje cell survival in rat cerebellar primary cultures,” Journal of Neuroscience Research, vol. 74, no. 5, pp. 754–759, 2003. View at: Publisher Site | Google Scholar
  7. Y. Yoshimi, S. Watanabe, T. Shinomiya, A. Makino, M. Toyoda, and M. Ikekita, “Nucleobase adenine as a trophic factor acting on Purkinje cells,” Brain Research, vol. 991, no. 1-2, pp. 113–122, 2003. View at: Publisher Site | Google Scholar
  8. J. Lüthje, “Extracellular adenine compounds, red blood cells and haemostasis: facts and hypotheses,” Blut, vol. 59, no. 4, pp. 367–374, 1989. View at: Google Scholar
  9. M. Han, X. Cheng, Z. Gao, R. Zhao, and S. Zhang, “Inhibition of tumor cell growth by adenine is mediated by apoptosis induction and cell cycle S phase arrest,” Oncotarget, vol. 8, no. 55, pp. 94286–94296, 2017. View at: Publisher Site | Google Scholar
  10. S. Y. Chen, C. H. Lin, J. T. Lin, Y. F. Cheng, H. M. Chen, and S. H. Kao, “Adenine causes cell cycle arrest and autophagy of chronic myelogenous leukemia K562 cells via AMP-activated protein kinase signaling,” Oncology Letters, vol. 14, pp. 5575–5580, 2017. View at: Publisher Site | Google Scholar
  11. G.-H. Young, J.-T. Lin, Y.-F. Cheng et al., “Identification of adenine modulating AMPK activation in NIH/3T3 cells by proteomic approach,” Journal of Proteomics, vol. 120, pp. 204–214, 2015. View at: Publisher Site | Google Scholar
  12. Y.-F. Cheng, G.-H. Young, J.-T. Lin et al., “Activation of AMP-activated protein kinase by adenine alleviates TNF-alpha-induced inflammation in human umbilical vein endothelial cells,” PLoS One, vol. 10, Article ID e0142283, 2015. View at: Publisher Site | Google Scholar
  13. D. Carling, “AMPK signalling in health and disease,” Current Opinion in Cell Biology, vol. 45, pp. 31–37, 2017. View at: Publisher Site | Google Scholar
  14. G. Rehman, A. Shehzad, A. L. Khan, and M. Hamayun, “Role of AMP-activated protein kinase in cancer therapy,” Archiv der Pharmazie, vol. 347, no. 7, pp. 457–468, 2014. View at: Publisher Site | Google Scholar
  15. A. Mogavero, M. V. Maiorana, S. Zanutto et al., “Metformin transiently inhibits colorectal cancer cell proliferation as a result of either AMPK activation or increased ROS production,” Scientific Reports, vol. 7, no. 1, p. 15992, 2017. View at: Publisher Site | Google Scholar
  16. B. Kou, W. Liu, X. Xu et al., “Autophagy induction enhances tetrandrine-induced apoptosis via the AMPK/mTOR pathway in human bladder cancer cells,” Oncology Reports, vol. 38, no. 5, pp. 3137–3143, 2017. View at: Publisher Site | Google Scholar
  17. J. Sesen, P. Dahan, S. J. Scotland et al., “Metformin inhibits growth of human glioblastoma cells and enhances therapeutic response,” PLoS One, vol. 10, Article ID e0123721, 2015. View at: Publisher Site | Google Scholar
  18. D. E. Kim, Y. Kim, D.-H. Cho et al., “Raloxifene induces autophagy-dependent cell death in breast cancer cells via the activation of AMP-activated protein kinase,” Molecules and Cells, vol. 38, no. 2, pp. 138–144, 2015. View at: Publisher Site | Google Scholar
  19. B. Ristic, M. Bosnjak, K. Arsikin et al., “Idarubicin induces mTOR-dependent cytotoxic autophagy in leukemic cells,” Experimental Cell Research, vol. 326, no. 1, pp. 90–102, 2014. View at: Publisher Site | Google Scholar
  20. J.-G. Leu, M.-H. Chiang, C.-Y. Chen et al., “Adenine accelerated the diabetic wound healing by PPAR delta and angiogenic regulation,” European Journal of Pharmacology, vol. 818, pp. 569–577, 2018. View at: Publisher Site | Google Scholar
  21. B.-P. Huang, C.-H. Lin, H.-M. Chen, J.-T. Lin, Y.-F. Cheng, and S.-H. Kao, “AMPK activation inhibits expression of proinflammatory mediators through downregulation of PI3K/p38 MAPK and NF-κB signaling in murine macrophages,” DNA and Cell Biology, vol. 34, no. 2, pp. 133–141, 2015. View at: Publisher Site | Google Scholar
  22. C.-C. Chen, J.-T. Lin, Y.-F. Cheng et al., “Amelioration of LPS-induced inflammation response in microglia by AMPK activation,” BioMed Research International, vol. 2014, Article ID 692061, 9 pages, 2014. View at: Publisher Site | Google Scholar
  23. B. Levine and G. Kroemer, “Autophagy in the pathogenesis of disease,” Cell, vol. 132, no. 1, pp. 27–42, 2008. View at: Publisher Site | Google Scholar
  24. F. Burada, E. R. Nicoli, M. E. Ciurea, D. C. Uscatu, M. Ioana, and D. I. Gheonea, “Autophagy in colorectal cancer: an important switch from physiology to pathology,” World Journal of Gastrointestinal Oncology, vol. 7, no. 11, pp. 271–284, 2015. View at: Publisher Site | Google Scholar
  25. K. Lai, M. C. Killingsworth, and C. S. Lee, “The significance of autophagy in colorectal cancer pathogenesis and implications for therapy,” Journal of Clinical Pathology, vol. 67, no. 10, pp. 854–858, 2014. View at: Publisher Site | Google Scholar
  26. K. Sato, K. Tsuchihara, S. Fujii et al., “Autophagy is activated in colorectal cancer cells and contributes to the tolerance to nutrient deprivation,” Cancer Research, vol. 67, no. 20, pp. 9677–9684, 2007. View at: Publisher Site | Google Scholar

Copyright © 2019 Hsin-Wu Lai et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

665 Views | 279 Downloads | 0 Citations
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.